We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical evaluation of the new topical anesthetic formulation in ß-thalassemia major patients.
- Authors
Zekavat OR; Samani SM; Nasibi S; Karimi M
- Abstract
Background Iran is among the most prevalent areas of major p-thalassemia. As thalassemic patients need repeated blood transfusion and deferoxamine injection, which is painfuL This study was performed to compare the effects of two new anesthetics products, (B4 and B6) with eutectic Mixture of Local Anesthetics (EMLA). Methods In a double-blind randomized, prospective, self-controlled trial, a total of 106 patients with an age range of 10-33 years who were referred to Shiraz Thalassemia Clinic, were enrolled in this study. In different referrals, 60 minutes after application of 2 gr EMLA, B4 and B6, the pain associated with insertion of a sterile 22 gauge needle into a depth of 2 mm of right forearm skin were assessed by visual analog pain scale. Results In deferoxamine injection, pain sensation was evaluated after application of 0.5 gram EMLA, B4 and B6. Mean ± SD intensity of pain sensation at the site of application of EMLA, B4 and B6 was 0,32(±1.41), 0.5 (±1.67) and 0.1 (±0.71) respectively. So, B6 was more potent than B4 and EMLA in pain reduction. In blood transfusion, pain sensation was evaluated after application of 0.5 gram of EMLA, B4 and B6. Mean intensity of pain sensation at the site of application was 0.57 (±1.62), 0.52 (±1.6) and 0.46 (±1.71) for EMLA, B4 and B6 respectively. Thus, B6 was more potent than B4 and EMLA, and B4 was more potent than EMLA in pain reduction. Conclusion B4 and B6 are low-priced and when considering their minor adverse effects compared to EMLA. Therefore, they can be substituted for EMLA in developing countries that have economical problems to provide EMLA.
- Publication
Journal of Applied Research, 2009, Vol 9, Issue 3, p63
- ISSN
1537-064X
- Publication type
Journal Article